Sentences with phrase «change cycle programming»

Paint programming, color change cycle programming.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Many factors could cause BlackBerry's actual results, performance or achievements to differ materially from those expressed or implied by the forward - looking statements, including, without limitation: BlackBerry's ability to enhance its current products and services, or develop new products and services in a timely manner or at competitive prices, including risks related to new product introductions; risks related to BlackBerry's ability to mitigate the impact of the anticipated decline in BlackBerry's infrastructure access fees on its consolidated revenue by developing an integrated services and software offering; intense competition, rapid change and significant strategic alliances within BlackBerry's industry; BlackBerry's reliance on carrier partners and distributors; risks associated with BlackBerry's foreign operations, including risks related to recent political and economic developments in Venezuela and the impact of foreign currency restrictions; risks relating to network disruptions and other business interruptions, including costs, potential liabilities, lost revenues and reputational damage associated with service interruptions; risks related to BlackBerry's ability to implement and to realize the anticipated benefits of its CORE program; BlackBerry's ability to maintain or increase its cash balance; security risks; BlackBerry's ability to attract and retain key personnel; risks related to intellectual property rights; BlackBerry's ability to expand and manage BlackBerry ® World ™; risks related to the collection, storage, transmission, use and disclosure of confidential and personal information; BlackBerry's ability to manage inventory and asset risk; BlackBerry's reliance on suppliers of functional components for its products and risks relating to its supply chain; BlackBerry's ability to obtain rights to use software or components supplied by third parties; BlackBerry's ability to successfully maintain and enhance its brand; risks related to government regulations, including regulations relating to encryption technology; BlackBerry's ability to continue to adapt to recent board and management changes and headcount reductions; reliance on strategic alliances with third - party network infrastructure developers, software platform vendors and service platform vendors; BlackBerry's reliance on third - party manufacturers; potential defects and vulnerabilities in BlackBerry's products; risks related to litigation, including litigation claims arising from BlackBerry's practice of providing forward - looking guidance; potential charges relating to the impairment of intangible assets recorded on BlackBerry's balance sheet; risks as a result of actions of activist shareholders; government regulation of wireless spectrum and radio frequencies; risks related to economic and geopolitical conditions; risks associated with acquisitions; foreign exchange risks; and difficulties in forecasting BlackBerry's financial results given the rapid technological changes, evolving industry standards, intense competition and short product life cycles that characterize the wireless communications industry.

The underlying assumption behind all the models in this chapter is that a congregation has an exciting possibility and responsibility to create a comprehensive marriage and family nurture program, beginning with remote preparation for marriage and extending through all the changing seasons of the life cycle of a family.

Shah said the $ 1.5 million budgeted for the digital program, which could change later in the cycle, is similar to what the group spent in 2014.

Dell's Plastics - Recycling Program Earns Green Electronics Award Only about 40 percent of used electronics are currently collected for recycling, and much of that is «down - cycled» into materials of lesser quality, but the computer company aims to change that.

After unsuccessfully lobbying to change those rules, Illingworth instead helped create a new «Early Release Science» (ERS) program to circumvent them — up to 500 hours of diverse observations front - loaded to Cycle 1 for immediate release to the public, giving all astronomers a chance to absorb the results and apply lessons learned to Webb proposals of their own.

The U.S. Global Change Research Program, which coordinates the National Climate Assessment report process, also released draft versions of two other reports for public comment: the Second State of the Carbon Cycle Report and the Fourth National Climate Assessment.

To counter the slow - changing nature of policy and service delivery, we need to embrace risk - taking, catalyze creative thinking, promote short - cycle sharing, learn quickly from failure, support continuous adaptation, and reject uncritical loyalty to existing programs or strategies.

Changing the Odds for Children at Risk: Seven Essential Principles of Educational Programs That Break the Cycle of Poverty.

With a staff committed to leading students to believe in their capabilities and a sound, low - cost reading program, teachers in Gilmer County Charter Schools are breaking the cycle of generational illiteracy and changing lives.

This cycle allows the ISD to gather data, evaluate programs, and implement changes to meet the needs of the districts we serve.

The government has shown this change in objectives in that «the number of magnet schools that receive MSAP [Magnet Schools Assistance Program] funding has declined in recent grant cycles because the overall funding level has remained stagnant and not adjusted for inflation at just over $ 100 million» (Frankenberg et al., 15).

By using computerized programs such as PC Bond, we can look at yield curve changes at similar points in past economic cycles in order to help us project future changes.

In relation to the previous cycle reads have few years of tradition, the authors of the program have made many changes, among which the foreground stands out even better visuals.

Posted in Research Blogging, tagged carbon cycle, climate change, climate models, education, geoengineering, global warming, ocean acidification, programming, science, sea ice on September 16, 2012 14 Comments»

It was developed as a component of the U.S. Interagency Carbon Cycle Science Program and as a contribution to U.S. climate change research planning.

HYDRA is part of the NERC CWC (Changing Water Cycle) program.

The US Global Change Research Program (USGCRP) released three major reports this afternoon: the final Climate Science Special Report (CSSR), the public review draft of the Fourth National Climate Assessment (NCA4) and the public review draft of the 2nd State of the Carbon Cycle Report (SOCCR - 2).

Through this program, NSF, DOE, NOAA, and the National Aeronautics and Space Administration (NASA) provided some $ 42 million for research on tectonics, coastal carbon cycles, sea - level change, and the historical record of climate and biological change.

Since 2009, US CLIVAR has collaborated with the OCB Program, whose mission is to study the impact of oceanic variability in the global carbon cycle in the face of environmental variability and change.

This involved working closely with the functional consultants to understand the functional specifications, incorporate changes from testing cycles and documenting the programs.

Tags for this Online Resume: Strategic Thought Leadership, IT Planning and Governance, Operational Management, Business Analysis, Global Team Building and Leadership, Managing Organizational Change, Software Development Life Cycle, Software Delivery Methodology, Executive / C - Level Relationship Management, Global Customer Management and Support, Large Scale Implementations, Product Development, Agile Scrum, Waterfall, RFP Responses and Sales Demonstrations, Business Process Re-engineering, Project and Program Management, Technical Solution Documentation

Tags for this Online Resume: Program Manager / Diretor, PLM / ERP (SAP / M2M) systems, Project Manager, PMI PMP Member / CMMI Trained / Six Sigma Green Belt Certified / ISO 9000 Certified / Life Cycle Management Trained, Business Change and IT Transformation, Merger & Acquisitions

Tags for this Online Resume: Strategic Alliance Development, IT Infrastructure, IT Design, Sales Cycle Management, Software Development, Account Management, Territory Management, Change Management, Strategic Planning, Team Leadership, Motivation, Sales Forecasting, Contract Negotiations, Sales Pipeline, Market Analysis, Branding, Presentations, Public Relations, Go - To - Market Solutions, Cloud - based Products, Executive Escalation, Cross-Industry, People Management, Budget Management, Large - Scale Partner Management Programs, Client Relations, Business Development, Project Management, IBM, OEM, Antioch, CA, California, 94531, Assistant Vice President, AVP, Strategic Partnership, ISV

The frenetic changing that accompanies each new electoral cycle can result in good programs being abandoned in favour of «new» programs that repeat the mistakes of the past.

During each implementation cycle, the program design changes to reflect the feedback of teachers so they can shape professional development.

At the end of the webinar, participants will be able to describe the changes to the new fifth edition of Work Sampling for Head Start and describe the components and assessment cycle of the program.

Amid a news cycle that changes by the minute, let's pause to recognize the importance of this program's reauthorization for families.

The Federal Housing Administration recently announced a cycle of new changes to its reverse mortgage program and most have already taken effect.